13th Mar 2024 15:48
GSK plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Sally Jackson | ||||
b) | Position/status | SVP, Global Communications & CEO Office | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GSK plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||
b) | Nature of the transaction | The sale of 9,000 Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | N/A (single transaction)
| ||||
e) | Date of the transaction | 2024-03-11 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Sally Jackson | ||||
b) | Position/status | SVP, Global Communications & CEO Office | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GSK plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||
b) | Nature of the transaction | The sale of 4,340 Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | N/A (single transaction)
| ||||
e) | Date of the transaction | 2024-03-11 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Dylan Jackson | ||||
b) | Position/status | PCA of Sally Jackson (SVP, Global Communications & CEO Office) | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GSK plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||
b) | Nature of the transaction | The sale of 13,616 Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | N/A (single transaction)
| ||||
e) | Date of the transaction | 2024-03-11 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Dylan Jackson | ||||
b) | Position/status | PCA of Sally Jackson (SVP, Global Communications & CEO Office) | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GSK plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||
b) | Nature of the transaction | The sale of 2,476 Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | N/A (single transaction)
| ||||
e) | Date of the transaction | 2024-03-12 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, GSK Global Health | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | The sale of 60,000 Ordinary Shares | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.8004 | 60,000 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2024-03-12 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Emma Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 7 (partnership shares) | ||||
£16.6610 | 7 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 14 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Julie Brown | |||
b) | Position/status | Chief Financial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 8 (partnership shares) | ||||
£16.6610 | 8 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 16 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | James Ford | |||
b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 8 (partnership shares) | ||||
£16.6610 | 8 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 16 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sally Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 7 (partnership shares) | ||||
£16.6610 | 7 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 14 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | President Corporate Development | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 8 (partnership shares) | ||||
£16.6610 | 8 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 16 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Regis Simard | |||
b) | Position/status | President, Global Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 8 (partnership shares) | ||||
£16.6610 | 8 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 16 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Philip Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 8 (partnership shares) | ||||
£16.6610 | 8 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 16 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 7 (partnership shares) | ||||
£16.6610 | 7 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 14 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Victoria Whyte | |||
b) | Position/status | Company Secretary | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.6610 | 7 (partnership shares) | ||||
£16.6610 | 7 (matching shares) | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 14 Ordinary Shares £16.6610 | ||||
e) | Date of the transaction | 2024-03-11 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
Related Shares:
Glaxosmithkline